Compare Inovio Pharmaceuticals Inc (INO) vs Iris Energy Limited (IREN) Price & Performance

Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.

The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.

IREN stock trades at $35.15, down 9.15% in the last 24 hours, reflecting bearish technical signals despite strong analyst buy ratings. The company reported revenue of $501.02M in 2025 with a net income of $86.94M, but recent quarterly EPS misses and a projected net loss of -$703M for 2026 highlight profitability challenges. Key developments include a $9.7 billion deal with Microsoft and a strategic pivot from Bitcoin mining to AI cloud services, positioning IREN in the high-growth AI infrastructure sector.

The outlook for IREN is mixed: significant upside exists from analyst price targets averaging $81.00, driven by AI demand and contracted revenue, but risks include execution on massive capital expenditure, intense competition, and current negative profitability. Investors face high volatility amid transformative growth ambitions versus near-term financial strain.